{
    "info": {
        "nct_id": "NCT01121562",
        "official_title": "A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors",
        "inclusion_criteria": "* Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor)\nHealthy volunteers allowed\nMust have minimum age of 20 Years",
        "exclusion_criteria": "* Patients with poorly differentiated neuroendocrine cancer are not eligible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor)",
            "criterions": [
                {
                    "exact_snippets": "advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor)",
                    "criterion": "pancreatic NET",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 20 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 20 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with poorly differentiated neuroendocrine cancer are not eligible",
            "criterions": [
                {
                    "exact_snippets": "poorly differentiated neuroendocrine cancer",
                    "criterion": "neuroendocrine cancer",
                    "requirements": [
                        {
                            "requirement_type": "differentiation",
                            "expected_value": "poorly differentiated"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}